journal
https://read.qxmd.com/read/38614036/synthesis-and-evaluation-of-novel-trifunctional-chelating-agents-for-pretargeting-approach-using-albumin-binder-to-improve-tumor-accumulation
#1
JOURNAL ARTICLE
Shohei Tsuchihashi, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono
INTRODUCTION: The pretargeting approach consists of in vivo ligation between pre-injected antibodies and low-molecular-weight radiolabeled effectors. The advantage of the pretargeting approach is to improve a tumor-to-background ratio, but the disadvantage is to compromise tumor accumulation. In this study, we applied albumin binder (ALB) to the pretargeting approach to overcome low tumor accumulation. METHODS: We synthesized two novel trifunctional effectors containing an ALB moiety, a chelator, and a different tetrazine and two corresponding effectors without an ALB moiety...
April 5, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38599145/tracking-the-fate-of-bacteria-derived-site-specific-immunomodulators-by-positron-emission-tomography
#2
JOURNAL ARTICLE
Alexia Kirby, Mojmír Suchý, Daniel Duan, Mark Bazett, Shirin Kalyan, Adam J Shuhendler
INTRODUCTION: Site-specific immunomodulators (SSIs) are a novel class of therapeutics made from inactivated bacterial species designed to regulate the innate immune system in targeted organs. QBECO is a gut-targeted SSI that is being advanced clinically to treat and/or prevent inflammatory bowel disease, cancer, and serious infections of the gastrointestinal (GI) tract and proximal organs, and QBKPN is a lung-targeted SSI that is in clinical development for the treatment and/or prevention of chronic inflammatory lung disease, lung cancers and respiratory tract infections...
March 28, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38599144/development-of-225-ac-213-bi-generator-based-on-%C3%AE-zrp-pan-composite-for-targeted-alpha-therapy
#3
JOURNAL ARTICLE
Lukáš Ondrák, Kateřina Ondrák Fialová, Michal Sakmár, Martin Vlk, Frank Bruchertseifer, Alfred Morgenstern, Ján Kozempel
BACKGROUND: Radioligand therapy using alpha emitters has gained more and more prominence in the last decade. Despite continued efforts to identify new appropriate radionuclides, the combination of 225 Ac/213 Bi remains among the most promising. Bismuth-213 has been employed in clinical trials in combination with appropriate vectors to treat patients with various forms of cancer, such as leukaemia, bladder cancer, neuroendocrine tumours, melanomas, gliomas, or lymphomas. However, the half-life of 213 Bi (T½  = 46 min) implies that its availability for clinical use is limited to hospitals possessing a 225 Ac/213 Bi radionuclide generator, which is still predominantly scarce...
March 28, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38599143/the-future-of-the-radiopharmaceutical-sciences
#4
EDITORIAL
Suzanne E Lapi, Peter J H Scott
No abstract text is available yet for this article.
March 27, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38555651/investigation-of-imaging-the-somatostatin-receptor-by-opening-the-blood-brain-barrier-with-melittin-a-feasibility-study-using-positron-emission-tomography-and-64-cu-cu-dotatate
#5
JOURNAL ARTICLE
Ida Vang Andersen, Natasha Shalina Rajani Bidesi, Vladimir Shalgunov, Jesper Tranekjær Jørgensen, Tobias Gustavsson, Kristian Strømgaard, Andreas T Ingemann Jensen, Andreas Kjær, Matthias M Herth
DOTATATE is a somatostatin peptide analog used in the clinic to detect somatostatin receptors which are highly expressed on neuroendocrine tumors. Somatostatin receptors are found naturally in the intestines, pancreas, lungs, and brain (mainly cortex). In vivo measurement of the somatostatin receptors in the cortex has been challenging because available tracers cannot cross the blood-brain barrier (BBB) due to their intrinsic polarity. A peptide called melittin, a main component of honeybee venom, has been shown to disrupt plasma membranes and increase the permeability of biological membranes...
March 19, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38518400/second-generation-al-18-f-labeled-d-amino-acid-peptide-for-cxcr4-targeted-molecular-imaging
#6
JOURNAL ARTICLE
Muriel Aline Spahn, Kaat Luyten, Tom Van Loy, Mike Sathekge, Christophe M Deroose, Michel Koole, Dominique Schols, Wim Vanduffel, Kristof De Vos, Pieter Annaert, Guy Bormans, Frederik Cleeren
BACKGROUND: The C-X-C chemokine receptor type 4 (CXCR4) is overexpressed in many cancers, e.g. multiple myeloma and acute leukemia, yet solely [68 Ga]PentixaFor is used for clinical PET imaging. The aim of this study was to develop and assess a second generation Al18 F-labeled D-amino acid peptide based on the viral macrophage inflammatory protein II for CXCR4 targeted molecular imaging. METHODS: We designed a library of monomer and multimer constructs and evaluated their binding affinity for human and mouse CXCR4...
March 19, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38493748/evaluation-of-acute-intravenous-toxicity-of-hepes-is-good-s-buffer-good-and-safe-enough-for-clinical-utilization-in-nuclear-medicine
#7
JOURNAL ARTICLE
Mohini Guleria, K J Pallavi, Pranjal P Gujarathi, Tapas Das
OBJECTIVE: Good's buffer or HEPES has advantages over other buffers commonly used in radiopharmaceutical preparation as it exhibits significantly lower complexation tendency with metal ions. However, use of HEPES buffer for radiolabeling reactions, meant for clinical applications, has been underrated due to the non-availability of sufficient toxicity data. The objective of the present study is to find the evidences towards safety of intravenous administration of HEPES through systemic toxicological studies in small animal model to support its safe application for clinical exploitation...
March 9, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38447298/improved-purification-of-cyclotron-68-ga-gacl-3-for-the-production-of-68-ga-radiopharmaceuticals
#8
JOURNAL ARTICLE
Ivan E Wang, Allen F Brooks, Mara Clark, Luke J Morrissette, Peter J H Scott
INTRODUCTION: Increased demand for NetSpot and Illuccix as requirement to receive the respective Lutathera and Pluvicto radiotherapies, and monitor subsequent response to treatment, have reinforced the need to develop alternative ways of producing gallium-68 (68 Ga). Building on our efforts to produce 68 Ga in a liquid target on a GE PETtrace, the goal of this work is to modify the current GE Gallium Chloride cassette using the FASTLab 2 synthesis module to produce [68 Ga]GaCl3 equivalent to a 1...
February 24, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38422917/serotonin-transporter-imaging-agent-as-a-probe-for-%C3%AE-cells-of-pancreas
#9
JOURNAL ARTICLE
Yuli Sun, Guangwen Li, Haiyan Hong, Lin Zhu, Hank F Kung, Yan Zhang, Jinxia Zhu
OBJECTIVE: Diabetes mellitus (DM) is one of the major diseases in the world. Nuclear medicine imaging may be able to detect functional status of pancreatic β cells in vivo, which might elucidate the pathological mechanisms of diabetes and develop individualized treatment plans. In this study, we evaluated the ability of [125 I]ADAM, a serotonin transporter (SERT) imaging agent, as a probe for detecting pancreatic β-cell mass (BCM). METHODS: In vitro cell studies were evaluated in INS-1 cells (rat islet β cell line)...
February 24, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38422918/development-of-a-ccr2-targeted-18-f-labeled-radiotracer-for-atherosclerosis-imaging-with-pet
#10
JOURNAL ARTICLE
Xiaohui Zhang, Lin Qiu, Debbie H Sultan, Hannah P Luehmann, Yanbo Yu, Xiuli Zhang, Gyu Seong Heo, Alexandria Li, Divangana Lahad, Shinji Rho, Zhude Tu, Yongjian Liu
Atherosclerosis is a chronic inflammatory disease and the leading cause of morbidity and mortality worldwide. CC motif chemokine ligand 2 and its corresponding cognate receptor 2 (CCL2/CCR2) signaling has been implicated in regulating monocyte recruitment and macrophage polarization during inflammatory responses that plays a pivotal role in atherosclerosis initiation and progression. In this study, we report the design and synthesis of a novel 18 F radiolabeled small molecule radiotracer for CCR2-targeted positron emission tomography (PET) imaging in atherosclerosis...
February 23, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38402673/biodistribution-study-of-211-pb-progeny-released-from-intravenously-applied-223-ra-labelled-tio-2-nanoparticles-in-a-mouse-model
#11
JOURNAL ARTICLE
Michal Sakmár, Ján Kozempel, Jan Kučka, Tereza Janská, Matěj Štíbr, Martin Vlk, Luděk Šefc
BACKGROUND: Targeted alpha therapy is one of the most powerful therapeutical modalities available in nuclear medicine. It's therapeutic potency is based on the nuclides that emit one or several alpha particles providing strong and highly localized therapeutic effects. However, some of these radionuclides, like e.g.223 Ra or 225 Ac decay in cascades, where the radioactive progeny originating from the consecutive alpha-decays may leave the original vector and cause unwanted irradiation of non-target organs...
February 19, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38330637/evaluation-of-targeting-%C3%AE-v-%C3%AE-3-in-breast-cancers-using-rgd-peptide-based-agents
#12
JOURNAL ARTICLE
Anders Josefsson, Angel G Cortez, Jing Yu, Sunipa Majumdar, Abhinav Bhise, Robert F Hobbs, Jessie R Nedrow
Patients with HER2-positive and triple negative breast cancer (TNBC) are associated with increased risk to develop metastatic disease including reoccurring disease that is resistant to standard and targeted therapies. The αV β3 has been implicated in BC including metastatic disease. The aims of this study were to investigate the potential of αV β3 -targeted peptides to deliver radioactive payloads to BC tumors expressing αV β3 on the tumor cells or limited to the tumors' neovascular...
February 6, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38340369/advancements-in-the-development-of-radiopharmaceuticals-for-nuclear-medicine-applications-in-the-treatment-of-bone-metastases
#13
JOURNAL ARTICLE
Michael R Dyer, Zhenghan Jing, Kathleen Duncan, Jacqueline Godbe, Monica Shokeen
Bone metastases are a painful and complex condition that overwhelmingly impacts the prognosis and quality of life of cancer patients. Over the years, nuclear medicine has made remarkable progress in the diagnosis and management of bone metastases. This review aims to provide a comprehensive overview of the recent advancements in nuclear medicine for the diagnosis and management of bone metastases. Furthermore, the review explores the role of targeted radiopharmaceuticals in nuclear medicine for bone metastases, focusing on radiolabeled molecules that are designed to selectively target biomarkers associated with bone metastases, including osteocytes, osteoblasts, and metastatic cells...
February 3, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38324923/imaging-diabetic-cardiomyopathy-in-a-type-1-diabetic-rat-model-using-18-f-feppa-pet
#14
JOURNAL ARTICLE
Hsin-Hua Hsieh, Pei-An Chu, Yu-Hsin Lin, Yu-Chieh Jill Kao, Yi-Hsiu Chung, Shih-Ting Hsu, Jia-Min Mo, Chun-Yi Wu, Shin-Lei Peng
OBJECTIVE: Diabetic patients often experience chronic inflammation and fibrosis in their cardiac tissues, highlighting the pressing need for the development of sensitive diagnostic methods for longitudinal assessment of diabetic cardiomyopathy. This study aims to evaluate the significance of an inflammatory marker known as translocator protein (TSPO) in a positron emission tomography (PET) protocol for longitudinally monitoring cardiac dysfunction in a diabetic animal model. Additionally, we compared the commonly used radiotracer, 18 F-fluoro-2-deoxy-d-glucose (18 F-FDG)...
January 26, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38232579/evaluation-of-f-537-tetrazine-in-a-model-for-brain-pretargeting-imaging-comparison-to-n-3-18-f-fluoro-5-1-2-4-5-tetrazin-3-yl-benzyl-propan-1-amine
#15
JOURNAL ARTICLE
Vladimir Shalgunov, Sara Lopes van den Broek, Ida Vang Andersen, Nakul R Raval, Gabriela Schäfer, Matthias Barz, Matthias M Herth, Umberto M Battisti
Brain pretargeted nuclear imaging for the diagnosis of various neurodegenerative diseases is a quickly developing field. The tetrazine ligation is currently the most explored approach to achieve this goal due to its remarkable properties. In this work, we evaluated the performance of F-537-Tetrazine, previously developed by Biogen, and N-(3-[18 F]fluoro-5-(1,2,4,5-tetrazin-3-yl)benzyl)propan-1-amine, previously developed in our group, thereby allowing for the direct comparison of these two imaging probes. The evaluation included synthesis, radiolabeling and a comparison of the physicochemical properties of the compounds...
January 11, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38241936/introduction-of-a-fatty-acid-chain-modification-to-prolong-circulatory-half-life-of-a-radioligand-towards-glucose-dependent-insulinotropic-polypeptide-receptor
#16
JOURNAL ARTICLE
Amina Khalil, Sona Hakhverdyan, Pierre Cheung, Martin Bossart, Michael Wagner, Olof Eriksson, Irina Velikyan
BACKGROUND: The beneficial role of glucose-dependent insulinotropic polypeptide receptor (GIPR) in weight control and maintaining glucose levels has led to the development of several multi-agonistic peptide drug candidates, targeting GIPR and glucagon like peptide 1 receptor (GLP1R) and/or the glucagon receptor (GCGR). The in vivo quantification of target occupancy by these drugs would accelerate the development of new drug candidates. The aim of this study was to evaluate a novel peptide (GIP1234), based on previously reported ligand DOTA-GIP-C803, modified with a fatty acid moiety to prolong its blood circulation...
January 10, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38199184/-64-cu-production-via-the-68-zn-p-n%C3%AE-64-cu-nuclear-reaction-an-untapped-cost-effective-and-high-energy-production-route
#17
JOURNAL ARTICLE
Bryce J B Nelson, Samantha Leier, John Wilson, Melinda Wuest, Jonathan Doupe, Jan D Andersson, Frank Wuest
INTRODUCTION: Copper-64 (64 Cu, t1/2  = 12.7 h) is a positron emitter well suited for theranostic applications with beta-emitting 67 Cu for targeted molecular imaging and radionuclide therapy. The present work aims to evaluate the radionuclidic purity and radiochemistry of 64 Cu produced via the 68 Zn(p,nα)64 Cu nuclear reaction. Macrocyclic chelators DOTA, NOTA, TETA, and prostate-specific membrane antigen ligand PSMA I&T were radiolabeled with purified 64 Cu and tested for in vitro stability...
January 6, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38458074/in-vitro-evaluation-of-3-h-pi-2620-and-structural-derivatives-in-non-alzheimer-s-tauopathies
#18
JOURNAL ARTICLE
Cassis Varlow, Chester A Mathis, Neil Vasdev
Alzheimer's disease (AD) and non-AD tauopathies such as chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) are characterized by the abnormal aggregation of three-repeat (3R) and/or four-repeat (4R) tau isoforms. Several tau-PET tracers have been applied for human imaging of AD and non-AD tauopathies including [18 F]PI-2620. Our objective is to evaluate [3 H]PI-2620 and two promising structural derivatives, [3 H]PI-2014 and [3 H]F-4, using in vitro saturation assays and competitive binding assays against new chemical entities based on this scaffold in human AD tissues for comparison with PSP, CBD and CTE tissues...
2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38154168/fully-automated-dual-run-manufacturing-of-11-c-pib-on-fastlab
#19
JOURNAL ARTICLE
Manoj Nair, Yiu-Yin Cheung, Fei Liu, Mary Ellen Koran, Adam J Rosenberg
This report describes an updated, fully automated method for the production of [11 C]PIB on a cassette-based automated synthesis module. The method allows for two separate productions of [11 C]PIB, both of which meet all specification for use in clinical studies. The GE FASTlab developer system was used to create the cassette design as well as the controlling tracer package. The method takes 16 min from the delivery of [11 C]MeOTf to the FASTlab, or 35 min from the End of Bombardment; and reliably produces 3547 ± 586 MBq of [11 C]PIB in high radiochemical purity (> 98 %)...
December 25, 2023: Nuclear Medicine and Biology
https://read.qxmd.com/read/38154167/chelation-chemistry-of-manganese-52-for-pet-imaging-applications
#20
JOURNAL ARTICLE
James M Omweri, Volkan Tekin, Shefali Saini, Hailey A Houson, Samith B Jayawardana, Daniel A Decato, Gayan B Wijeratne, Suzanne E Lapi
INTRODUCTION: Due to its decay and chemical properties, interest in manganese-52 has increased for development of long-lived PET radiopharmaceuticals. Its long half-life of 5.6 days, low average positron energy (242 keV), and sufficient positron decay branching ratio make it suitable for radiolabeling macromolecules for investigating slow biological processes. This work aims to establish suitable chelators for manganese-52 that can be radiolabeled at mild conditions through the evaluation of commercially available chelators...
December 23, 2023: Nuclear Medicine and Biology
journal
journal
31285
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.